Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Zeptomole per milliliter detection and quantification of edema factor in plasma by LC-MS/MS yields insights into toxemia and the progression of inhalation anthrax.

Lins RC, Boyer AE, Kuklenyik Z, Woolfitt AR, Goldstein J, Hoffmaster AR, Gallegos-Candela M, Leysath CE, Chen Z, Brumlow JO, Quinn CP, Bagarozzi DA Jr, Leppla SH, Barr JR.

Anal Bioanal Chem. 2019 May;411(12):2493-2509. doi: 10.1007/s00216-019-01730-4. Epub 2019 Mar 26.

PMID:
30911800
2.

Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting.

Chen KH, Liu S, Leysath CE, Miller-Randolph S, Zhang Y, Fattah R, Bugge TH, Leppla SH.

J Biol Chem. 2016 Oct 14;291(42):22021-22029. Epub 2016 Aug 23.

3.

A heterodimer of a VHH (variable domains of camelid heavy chain-only) antibody that inhibits anthrax toxin cell binding linked to a VHH antibody that blocks oligomer formation is highly protective in an anthrax spore challenge model.

Moayeri M, Leysath CE, Tremblay JM, Vrentas C, Crown D, Leppla SH, Shoemaker CB.

J Biol Chem. 2015 Mar 6;290(10):6584-95. doi: 10.1074/jbc.M114.627943. Epub 2015 Jan 6.

4.

Reductive methylation and mutation of an anthrax toxin fusion protein modulates its stability and cytotoxicity.

Bachran C, Gupta PK, Bachran S, Leysath CE, Hoover B, Fattah RJ, Leppla SH.

Sci Rep. 2014 Apr 23;4:4754. doi: 10.1038/srep04754.

5.

Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins.

Bachran C, Hasikova R, Leysath CE, Sastalla I, Zhang Y, Fattah RJ, Liu S, Leppla SH.

Cell Death Dis. 2014 Jan 16;5:e1003. doi: 10.1038/cddis.2013.540.

6.

A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2.

Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB.

Infect Immun. 2013 Dec;81(12):4592-603. doi: 10.1128/IAI.01033-13. Epub 2013 Sep 30.

7.

Anthrax edema factor toxicity is strongly mediated by the N-end rule.

Leysath CE, Phillips DD, Crown D, Fattah RJ, Moayeri M, Leppla SH.

PLoS One. 2013 Aug 28;8(8):e74474. doi: 10.1371/journal.pone.0074474. eCollection 2013.

8.

The sub-nanomolar binding of DNA-RNA hybrids by the single-chain Fv fragment of antibody S9.6.

Phillips DD, Garboczi DN, Singh K, Hu Z, Leppla SH, Leysath CE.

J Mol Recognit. 2013 Aug;26(8):376-81. doi: 10.1002/jmr.2284.

9.

Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors.

Phillips DD, Fattah RJ, Crown D, Zhang Y, Liu S, Moayeri M, Fischer ER, Hansen BT, Ghirlando R, Nestorovich EM, Wein AN, Simons L, Leppla SH, Leysath CE.

J Biol Chem. 2013 Mar 29;288(13):9058-65. doi: 10.1074/jbc.M113.452110. Epub 2013 Feb 7.

10.

A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.

Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB.

PLoS One. 2012;7(1):e29941. doi: 10.1371/journal.pone.0029941. Epub 2012 Jan 6.

11.

Mouse monoclonal antibodies to anthrax edema factor protect against infection.

Leysath CE, Chen KH, Moayeri M, Crown D, Fattah R, Chen Z, Das SR, Purcell RH, Leppla SH.

Infect Immun. 2011 Nov;79(11):4609-16. doi: 10.1128/IAI.05314-11. Epub 2011 Sep 12.

12.

Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex.

Radjainia M, Hyun JK, Leysath CE, Leppla SH, Mitra AK.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14070-4. doi: 10.1073/pnas.1006473107. Epub 2010 Jul 26.

13.

Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen.

Leysath CE, Monzingo AF, Maynard JA, Barnett J, Georgiou G, Iverson BL, Robertus JD.

J Mol Biol. 2009 Apr 3;387(3):680-93. doi: 10.1016/j.jmb.2009.02.003. Epub 2009 Feb 10.

14.

Engineering antibody fragments to fold in the absence of disulfide bonds.

Seo MJ, Jeong KJ, Leysath CE, Ellington AD, Iverson BL, Georgiou G.

Protein Sci. 2009 Feb;18(2):259-67. doi: 10.1002/pro.31.

15.

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.

Jin L, Tabe Y, Konoplev S, Xu Y, Leysath CE, Lu H, Kimura S, Ohsaka A, Rios MB, Calvert L, Kantarjian H, Andreeff M, Konopleva M.

Mol Cancer Ther. 2008 Jan;7(1):48-58. doi: 10.1158/1535-7163.MCT-07-0042.

16.

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.

Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A, Schober WD, Harris D, Leysath CE, Lopez-Berestein G, Huang Z, Andreeff M.

Blood. 2002 May 1;99(9):3461-4.

17.

Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M.

Blood. 2002 Jan 1;99(1):326-35.

18.

Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD86 (B7-2).

Morton PA, Fu XT, Stewart JA, Giacoletto KS, White SL, Leysath CE, Evans RJ, Shieh JJ, Karr RW.

J Immunol. 1996 Feb 1;156(3):1047-54.

PMID:
8557978

Supplemental Content

Loading ...
Support Center